Kyverna Therapeutics, Inc.
KYTX
$9.40
$0.040.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -161.31M | -160.99M | -158.70M | -145.42M | -127.48M |
| Total Depreciation and Amortization | 1.80M | 1.99M | 2.14M | 2.15M | 2.13M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.87M | 4.53M | 3.82M | 2.12M | 3.24M |
| Change in Net Operating Assets | -1.08M | -2.78M | 11.33M | 7.51M | 7.86M |
| Cash from Operations | -153.71M | -157.25M | -141.41M | -133.64M | -114.25M |
| Capital Expenditure | -5.00K | -538.00K | -638.00K | -1.66M | -2.21M |
| Sale of Property, Plant, and Equipment | 70.00K | 70.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.95M | 86.99M | 65.28M | -30.78M | -158.70M |
| Cash from Investing | 40.02M | 86.52M | 64.64M | -32.45M | -160.90M |
| Total Debt Issued | 24.70M | -- | -- | -- | -- |
| Total Debt Repaid | -808.00K | -970.00K | -1.09M | -1.07M | -956.00K |
| Issuance of Common Stock | 117.90M | 1.69M | 125.00K | 198.00K | 341.43M |
| Repurchase of Common Stock | -144.00K | -94.00K | -51.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -475.00K | -412.00K | -412.00K | -482.00K | -3.36M |
| Cash from Financing | 141.17M | 210.00K | -1.43M | -1.35M | 337.11M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 27.47M | -70.51M | -78.20M | -167.44M | 61.96M |